Scientific deep-dive
Retatrutide for type 2 diabetes: TRIUMPH-2 Phase 3 results and Phase 2 evidence
Retatrutide is investigational and not FDA-approved. In TRIUMPH-2 (Lancet 2026, n=1,152, placebo-controlled), adults with obesity and T2D lost 18.8% of body weight on 12 mg vs 5.1% on placebo at 80 weeks. Lilly plans an FDA filing in Q1 2027.
This evidence review is part of Weight Loss Rankings’ living editorial database — 1,180+ research articles and 640+ editorially reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.
Retatrutide is an Eli Lilly investigational triple agonist at the GIP, GLP-1, and glucagon receptors. It is NOT FDA-approved — for type 2 diabetes or any other indication — anywhere worldwide as of October 2026. The dedicated Phase 3 trial in adults with obesity and type 2 diabetes, TRIUMPH-2 (ClinicalTrials.gov NCT05929079), was published in The Lancet in 2026: at 80 weeks, body weight fell 11.9%, 16.8%, and 18.8% on retatrutide 4, 9, and 12 mg versus 5.1% on placebo[11]. TRIUMPH-2 was placebo-controlled; the only retatrutide T2D trial with an active comparator remains the Phase 2 Rosenstock 2023 trial versus dulaglutide (PMID 37385280). Lilly plans to submit a Biologics License Application to the FDA in Q1 2027[13]. The FDA-approved precedent for this drug family in T2D is tirzepatide (Mounjaro, approved May 13, 2022), a dual GIP/GLP-1 receptor agonist. This article walks through the TRIUMPH-2 Phase 3 results, what the Phase 2 T2D trial showed, the body composition substudy (Coskun 2025), the appetite substudy (Kanu 2025), the mechanistic rationale (Coskun 2022, Li 2024), and the SURPASS and SUSTAIN reference points needed to interpret cross-trial comparisons.
The honest answer
Retatrutide is investigational only. It is NOT FDA-approved for T2D (or any indication) anywhere worldwide as of October 2026. The Phase 3 TRIUMPH-2 trial (Lancet 2026) showed 18.8% average weight loss on 12 mg versus 5.1% on placebo over 80 weeks in adults with obesity and type 2 diabetes. Lilly plans to file with the FDA in Q1 2027. The FDA-approved option in this drug family today is tirzepatide (Mounjaro, May 13 2022).
At a glance
- Not FDA-approved. Retatrutide (LY3437943) is investigational only as of October 2026 — not approved for T2D, for obesity, for sleep apnea, or for any indication worldwide. Lilly plans to submit a Biologics License Application in Q1 2027[13].
- TRIUMPH-2 Phase 3 (Lancet 2026, PMID 42810372) — 1,152 adults with obesity or overweight and type 2 diabetes, placebo-controlled. Body weight at 80 weeks: -11.9% / -16.8% / -18.8% (4 / 9 / 12 mg) vs -5.1% placebo; differences vs placebo -6.9, -11.8, and -13.8 percentage points (p<0.0001)[11].
- Triple agonist mechanism. Simultaneous engagement of GIP, GLP-1, and glucagon receptors with a GIP-favored activity profile (more GIPR activity, balanced GCGR and GLP-1R activity) designed to balance glucagon-driven energy expenditure against hyperglycemia risk[2].
- Rosenstock 2023 (PMID 37385280) — Phase 2 T2D trial in 281 adults. HbA1c at 24 weeks: -0.43% / -1.39% / -1.30% / -1.99% / -1.88% / -2.02% across ascending retatrutide arms versus -0.01% placebo and -1.41% dulaglutide 1.5 mg[1].
- 36-week weight reductions in Rosenstock 2023 reached -16.94% at retatrutide 12 mg, vs -3.00% placebo and -2.02% dulaglutide[1].
- Body composition substudy (Coskun 2025, PMID 40609566): fat mass loss dose-dependent up to 26.1% at the 8 mg pooled arm; lean-to-total-weight-loss ratio similar to other obesity drugs[5].
- NO severe hypoglycemia, no deaths across all 281 Phase 2 participants — consistent with glucose-dependent incretin secretion when used without insulin or sulfonylurea[1].
- TRANSCEND-T2D-1 Phase 3 (Lancet 2026, PMID 42250575) — 537 adults with T2D on diet and exercise alone, placebo-controlled, 40 weeks. HbA1c: -1.69% / -1.86% / -1.94% (4 / 9 / 12 mg) vs -0.81% placebo; body weight -11.5% / -13.9% / -15.3% vs -2.6%; no severe hypoglycemia[15].
- TRIUMPH-2 tolerability: GI events were the most common adverse events (nausea 28% and diarrhea 34% at 12 mg vs 8% and 13% on placebo); hypotension and dysesthesia were also more frequent than on placebo[11].
What type 2 diabetes is, and why triple agonism matters
Type 2 diabetes (T2D) is a chronic metabolic condition characterized by insulin resistance and progressive beta-cell dysfunction. Hallmark clinical features include elevated fasting glucose, elevated HbA1c (typically ≥ 6.5%, the ADA diagnostic threshold), and progressive risk of cardiovascular, renal, retinal, and neuropathic complications when glycemic control is not maintained. The therapeutic goal in pharmacologic T2D management is to reduce HbA1c to an individualized target (typically < 7.0% for most non-pregnant adults, per ADA guidance) while minimizing hypoglycemia risk and addressing weight, cardiovascular, and renal comorbidities.
The modern T2D pharmacologic landscape uses several mechanistic classes: biguanides (metformin), SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, basal and prandial insulins, selective GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide), and — since the Mounjaro approval on May 13, 2022 — the dual GIP/GLP-1 receptor agonist tirzepatide. Each class engages different physiological levers for glucose control and weight effect.
The triple GIP/GLP-1/glucagon mechanism is conceptually distinct because it adds a glucagon-receptor-agonist arm on top of the incretin mechanisms. The biological rationale: glucagon receptor agonism increases hepatic glucose output and resting energy expenditure (calorie burn), but in isolation would worsen glycemic control. When combined with potent GIP and GLP-1 agonism — which together drive insulin secretion in a glucose-dependent manner, suppress glucagon secretion in the hyperglycemic state, and delay gastric emptying — the net effect on HbA1c can remain favorable while capturing the energy-expenditure benefit. The Coskun 2022 Cell Metab paper details the GIP-favored receptor activity ratio designed to achieve this balance[2].
TRIUMPH-2 confirmed that the triple mechanism produces substantial weight loss in T2D versus placebo, but because it had no tirzepatide arm, whether it produces clinically meaningfully larger A1c or weight reductions than tirzepatide remains unanswered. For the broader mechanism review across indications, see retatrutide triple-agonist evidence review.
Mechanism primer: how retatrutide works
Retatrutide (Eli Lilly compound LY3437943) is a single-molecule peptide agonist that simultaneously engages three incretin-superfamily receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). The compound’s discovery and proof-of-concept characterization were published in Coskun 2022 Cell Metab (PMID 35985340), which describes the molecular design choices intended to balance the three signaling pathways[2].
Key design features:
- Receptor activity profile. Coskun 2022 reports the in vitro profile as balanced GCGR and GLP-1R activity, with more GIPR activity. GIP-favored activity is intended to maximize the incretin glucose-dependent insulin secretion effect; GLP-1R activity contributes additional insulinotropic, anorectic, and gastric-emptying effects; GCGR activity is intended to engage hepatic glucose handling and resting energy expenditure without overwhelming the incretin-driven glycemic control.
- Once-weekly subcutaneous administration. The peptide was engineered for a half-life consistent with once-weekly dosing — matching the prevailing dosing cadence for tirzepatide, semaglutide, and dulaglutide.
- Delayed gastric emptying. Urva 2023 Diabetes Obes Metab (PMID 37311727) demonstrated measurable retatrutide-induced delay of gastric emptying, consistent with the GLP-1R agonist class and contributing both to the postprandial glucose effect and to the dose-dependent gastrointestinal side-effect profile observed in clinical trials[4].
- Structural basis. Li 2024 Cell Discov (PMID 39019866) published cryo-electron microscopy structures of retatrutide engaged with each of the three receptors, providing the structural framework for understanding the simultaneous receptor engagement[3].
The clinical Phase 2 program tested whether this molecular profile translates into clinically meaningful T2D efficacy and acceptable safety. Rosenstock 2023 is the Phase 2 T2D readout.
The Phase 2 T2D pivotal: Rosenstock 2023 in detail
Rosenstock 2023 Lancet (PMID 37385280) was the first Phase 2 retatrutide trial in type 2 diabetes and remains the only one with an active comparator (dulaglutide 1.5 mg); TRIUMPH-2, covered below, is now the larger Phase 3 evidence base[1]. Design and population:
- Trial design. Randomized, double-blind, placebo- and active-controlled, parallel-group, Phase 2, multicenter trial conducted in the USA. ClinicalTrials.gov NCT04867785.
- Population. Adults with type 2 diabetes inadequately controlled on diet and exercise alone OR on metformin monotherapy. n=281 randomized across 8 arms.
- Eight arms. Placebo (n=45); dulaglutide 1.5 mg weekly active comparator (n=46); retatrutide 0.5 mg weekly (n=47); retatrutide 4 mg with escalation schedule (n=23); retatrutide 4 mg with no escalation (n=24); retatrutide 8 mg with slow escalation (n=26); retatrutide 8 mg with fast escalation (n=24); retatrutide 12 mg with escalation (n=46). 275 patients were included in efficacy analyses. 237 patients (84%) completed the trial.
- Primary endpoint. Change in HbA1c from baseline to 24 weeks.
- Treatment duration. 36-week intervention period with the primary endpoint at 24 weeks.
Headline glycemic results at the 24-week primary endpoint (LS-mean change in HbA1c from baseline):
- Placebo: -0.01 percentage points (essentially no change).
- Dulaglutide 1.5 mg: -1.41 percentage points.
- Retatrutide 0.5 mg: -0.43 percentage points.
- Retatrutide 4 mg (escalation): -1.39 percentage points.
- Retatrutide 4 mg (no escalation): -1.30 percentage points.
- Retatrutide 8 mg (slow escalation): -1.99 percentage points.
- Retatrutide 8 mg (fast escalation): -1.88 percentage points.
- Retatrutide 12 mg (escalation): -2.02 percentage points.
Statistical comparisons versus the dulaglutide 1.5 mg active comparator were reported. Retatrutide 8 mg slow escalation produced statistically significantly greater HbA1c reduction than dulaglutide (p=0.0019), and retatrutide 12 mg also produced statistically significantly greater HbA1c reduction (p=0.0002). The lower retatrutide doses (0.5 mg and 4 mg arms) were not statistically superior to dulaglutide[1].
Body-weight reductions at 36 weeks were dose-dependent:
- Placebo: -3.00%.
- Dulaglutide 1.5 mg: -2.02%.
- Retatrutide 0.5 mg: -3.19%.
- Retatrutide 4 mg escalation: -7.92%.
- Retatrutide 4 mg no escalation: -10.37%.
- Retatrutide 8 mg slow escalation: -16.81%.
- Retatrutide 8 mg fast escalation: -16.34%.
- Retatrutide 12 mg escalation: -16.94%.
All retatrutide arms at ≥ 4 mg produced statistically significantly greater body-weight reduction than dulaglutide 1.5 mg (P<0.0001). The magnitude of body-weight reduction at the 8 mg and 12 mg doses (approximately 16-17%) is larger than what tirzepatide 15 mg produced in SURPASS-2 on a metformin background — though direct cross-trial comparison is not statistically valid (different populations, different durations, different active comparators)[8].
Safety highlights from Rosenstock 2023:
- No severe hypoglycemia across any of the 281 participants. No deaths.
- Mild-to-moderate gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were reported in approximately 35% of retatrutide-treated patients pooled, ranging from 13% at the 0.5 mg dose to 50% at the 8 mg fast-escalation dose. Placebo GI AE rate was 13% and dulaglutide GI AE rate was 35%.
- GI events were dose-dependent and escalation-schedule-dependent. At a matched final dose, slow escalation produced a lower GI burden than fast escalation — the same pattern observed with tirzepatide and semaglutide.
Magnitude comparison
Rosenstock 2023 Phase 2 T2D — LS-mean HbA1c reduction at 24 weeks across placebo, dulaglutide 1.5 mg active comparator, and retatrutide ascending-dose arms. Retatrutide 8 mg slow escalation and 12 mg escalation produced statistically significantly greater HbA1c reduction than dulaglutide 1.5 mg. No severe hypoglycemia or deaths were reported.[1]
- Placebo0.01 % pointsessentially no change
- Dulaglutide 1.5 mg (active comparator)1.41 % points
- Retatrutide 0.5 mg0.43 % points
- Retatrutide 4 mg (escalation)1.39 % points
- Retatrutide 8 mg (slow escalation)1.99 % pointsp=0.0019 vs dulaglutide
- Retatrutide 12 mg (escalation)2.02 % pointsp=0.0002 vs dulaglutide
Body composition substudy: Coskun 2025
The Coskun 2025 Lancet Diabetes Endocrinol body-composition substudy (PMID 40609566) reports DXA-measured fat mass and lean mass changes in a subset of the Rosenstock 2023 trial participants[5]. Substudy participation:
- n=189 enrolled into the body composition substudy across the eight Rosenstock 2023 arms.
- n=155 with baseline DXA scans.
- n=103 with paired baseline + 36-week DXA scans (the analysis population for paired comparisons).
Fat mass percentage reduction at 36 weeks:
- Placebo: 4.5%.
- Dulaglutide 1.5 mg: 2.6%.
- Retatrutide 0.5 mg: 4.9%.
- Retatrutide 4 mg (pooled escalation + no-escalation arms): 15.2%.
- Retatrutide 8 mg (pooled slow + fast escalation arms): 26.1%.
- Retatrutide 12 mg: 23.2%.
LS-mean fat mass change versus placebo:
- Retatrutide 0.5 mg: -0.4 percentage points (p=0.83, not significant).
- Retatrutide 4 mg pooled: -10.7 percentage points (p=0.0013).
- Retatrutide 8 mg pooled: -21.6 percentage points (p<0.0001).
- Retatrutide 12 mg: -18.7 percentage points (p<0.0001).
The critical body composition finding: the proportion of lean mass loss relative to total weight loss was similar to what other obesity treatments produce. In other words, retatrutide did not produce a disproportionately greater lean-mass loss than what is observed with FDA-approved incretin-class agents at comparable weight-loss magnitudes. The lean-loss ratio interpretation provides reassurance that the large absolute weight reductions are driven primarily by fat mass reduction, not by excess lean tissue catabolism[5].
For the practical implications of GLP-1-class lean-mass loss and the role of resistance training, see related discussion in the broader retatrutide evidence review at retatrutide triple-agonist evidence.
Appetite and eating behavior: Kanu 2025
The Kanu 2025 Diabetes Obesity & Metabolism substudy (PMID 40916752) reports appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) measurements during the Rosenstock 2023 Phase 2 trial[6]. Substudy design:
- n=275 Phase 2 T2D adults assessed at weeks 24 and 36.
- Appetite VAS. Validated visual analog scale measurements of overall appetite, hunger, satiety, prospective food consumption, and desire to eat.
- Eating Inventory (EI). Validated three-factor questionnaire measuring Dietary Restraint, Disinhibition, and Perceived Hunger.
Key findings:
- Retatrutide ≥ 4 mg reduced overall appetite, hunger, and prospective food consumption versus placebo (p<0.05).
- EI Perceived Hunger and Disinhibition improved at retatrutide 8 mg and 12 mg at both weeks 24 and 36.
- EI Dietary Restraint increased versus placebo only at the 12 mg dose at week 36.
- Behavioral correlations with weight loss: reductions in Perceived Hunger correlated with weight loss (r = 0.28); reductions in Disinhibition correlated with weight loss (r = 0.36); increases in Dietary Restraint correlated with weight loss (r = 0.31).
The behavioral pattern is consistent with the incretin-class appetite-suppression mechanism: reduced hunger and reduced disinhibited eating, paired with increased dietary restraint, all contributing to the energy-deficit substrate for weight loss. This mechanistic profile is similar to what has been characterized for semaglutide and tirzepatide in their respective Phase 3 obesity programs.
Head-to-head context: SURPASS-1, SURPASS-2, SUSTAIN-7
Cross-trial comparisons between Rosenstock 2023 retatrutide Phase 2 data and the FDA-approved comparators are not statistically valid (different durations, different populations, different active comparators). The reference points below are useful for orientation only.
SURPASS-1 (Rosenstock 2021): tirzepatide monotherapy benchmark
SURPASS-1 (PMID 34186022) was a 40-week, double-blind, placebo- controlled, Phase 3 trial in 478 drug-naive T2D adults randomized to tirzepatide 5/10/15 mg weekly vs placebo[9]. HbA1c reductions were -1.87% / -1.89% / -2.07% at the three tirzepatide doses versus +0.04% on placebo (all P<0.0001). Dose-dependent weight reduction ranged from 7.0 to 9.5 kg. SURPASS-1 is the FDA-approved dual GIP/GLP-1 monotherapy benchmark for T2D.
SURPASS-2 (Frías 2021): tirzepatide vs semaglutide head-to-head
SURPASS-2 (PMID 34170647) was a 40-week, open-label, Phase 3 trial in 1,879 T2D adults on metformin background, randomized to tirzepatide 5/10/15 mg weekly versus semaglutide 1 mg weekly[8]. HbA1c reductions were -2.01 / -2.24 / -2.30 percentage points (tirzepatide) versus -1.86 (semaglutide). Body-weight treatment differences versus semaglutide were -1.9 kg, -3.6 kg, and -5.5 kg respectively (all P<0.001). SURPASS-2 is the closest FDA-approved precedent for the question retatrutide now faces — “does adding a receptor target beat a narrower incretin mechanism in T2D?” — and there tirzepatide’s dual GIP/GLP-1 mechanism beat semaglutide’s selective GLP-1 mechanism on both endpoints. Whether a third (glucagon) target adds more will take a head-to-head trial to settle.
SUSTAIN-7 (Pratley 2018): semaglutide vs dulaglutide
SUSTAIN-7 (PMID 29397376) was a 40-week, open-label, Phase 3b trial in 1,201 T2D adults randomized to semaglutide 0.5 mg or 1.0 mg weekly versus dulaglutide 0.75 mg or 1.5 mg weekly[10]. HbA1c reductions: sema 0.5 mg -1.5% vs dula 0.75 mg -1.1% (estimated treatment difference -0.40, P<0.0001); sema 1.0 mg -1.8% vs dula 1.5 mg -1.4% (ETD -0.41, P<0.0001). Weight: sema 1.0 mg -6.5 kg vs dula 1.5 mg -3.0 kg (P<0.0001). SUSTAIN-7 is the closest GLP-1-only comparator scaffold for understanding what dulaglutide 1.5 mg — the active comparator in Rosenstock 2023 — looks like across the broader GLP-1 class. Lined up against retatrutide’s own T2D data, SUSTAIN-7 is also the anchor for the indirect retatrutide-versus-Ozempic comparison.
The implication: retatrutide 12 mg in Phase 2 (HbA1c -2.02% at 24 wk vs dulaglutide 1.5 mg -1.41%) and tirzepatide 15 mg in SURPASS-2 (HbA1c -2.30% at 40 wk vs semaglutide 1 mg -1.86%) are roughly comparable in magnitude, but the trial designs differ. TRIUMPH-2 compared retatrutide with placebo, not tirzepatide, so no direct retatrutide vs tirzepatide claim in T2D is supported yet. For more cross-trial analysis, see retatrutide vs tirzepatide head-to-head evidence and how Mounjaro, Ozempic and Trulicity compare in T2D, SURPASS-2 included.
TRIUMPH-2 Phase 3: the published results
TRIUMPH-2 (ClinicalTrials.gov NCT05929079) is Eli Lilly’s Phase 3 registrational trial of retatrutide in adults with obesity or overweight and type 2 diabetes, published in The Lancet in 2026 (Bellido 2026, PMID 42810372)[11]. The broader TRIUMPH program design is summarized in Giblin 2026 Diabetes Obes Metab (PMID 41090431)[7]. Design and population:
- Trial design. Double-blind, parallel-group, randomized, placebo-controlled Phase 3 trial at 92 sites in eight countries. There was no active comparator arm (no dulaglutide, semaglutide, or tirzepatide).
- Population. Adults with BMI ≥ 27 kg/m² and type 2 diabetes (HbA1c 6.5–10.5%) on diet and exercise alone or up to three oral glucose-lowering medications. n=1,152 randomized 1:1:1:1 to placebo or retatrutide 4, 9, or 12 mg weekly. Mean baseline BMI 38.2 kg/m² mean baseline HbA1c 7.71%.
- Primary endpoint. Percent change in body weight from baseline to week 80 for 9 mg and 12 mg versus placebo (4 mg versus placebo was a key secondary endpoint), analyzed with the treatment-regimen estimand in all randomized participants.
- Status. Completed (primary completion June 16, 2026, per ClinicalTrials.gov).
Weight results at 80 weeks (treatment-regimen estimand): -11.9% on 4 mg, -16.8% on 9 mg, and -18.8% on 12 mg versus -5.1% on placebo. Estimated treatment differences versus placebo were -6.9 (95% CI -8.7 to -5.1), -11.8 (-13.7 to -9.8), and -13.8 (-15.8 to -11.8) percentage points (p<0.0001 for all)[11]. The paper’s abstract reports improved glycemic control without giving HbA1c figures; Lilly’s July 2026 topline release, which uses the efficacy estimand (participants who stayed on treatment), reported HbA1c reductions of 1.4, 1.6, and 1.5 points on 4, 9, and 12 mg versus 0.2 on placebo from a baseline of 7.7%[12].
Magnitude comparison
TRIUMPH-2 (Bellido 2026 Lancet) — mean percent change in body weight at 80 weeks in adults with obesity and type 2 diabetes, treatment-regimen estimand. Placebo-controlled; no active comparator.[11]
- Placebo5.1 % body weight
- Retatrutide 4 mg11.9 % body weight
- Retatrutide 9 mg16.8 % body weight
- Retatrutide 12 mg18.8 % body weight-13.8 pp vs placebo
Safety highlights from TRIUMPH-2[11]:
- Gastrointestinal events were most common. Diarrhea occurred in 27%, 34%, and 34% (4 / 9 / 12 mg) versus 13% on placebo; nausea in 14%, 21%, and 28% versus 8%.
- Hypotension and dysesthesia (abnormal skin sensations) were more frequent than on placebo: hypotension 1%, 5%, and 6% versus <1%; dysesthesia 4%, 6%, and 7% versus 1%.
- Stopping treatment. Permanent discontinuation due to adverse events or death was 4% on 4 mg, 12% on 9 mg, and 8% on 12 mg versus 5% on placebo.
- Deaths. Seven participants died (two, three, and one in the 4, 9, and 12 mg groups; one on placebo); investigators judged none related to the study drug.
Note that TRIUMPH-2’s weight loss (18.8% at 12 mg) is smaller than the 25.0% reported at the same dose in TRIUMPH-1, which enrolled adults with obesity but without diabetes (NEJM 2026)[14]. The trials enrolled different populations, so the gap should not be read as a head-to-head result. Retatrutide is still not FDA-approved; Lilly plans to submit a Biologics License Application in Q1 2027[13]. For the broader regulatory and access timeline, see retatrutide approval and access timeline.
A second Phase 3 trial: TRANSCEND-T2D-1
TRANSCEND-T2D-1 (Bajaj 2026 Lancet, PMID 42250575; NCT06354660) is a separate 40-week, double-blind, placebo-controlled Phase 3 trial of retatrutide as monotherapy in 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone (mean baseline HbA1c 7.9%, mean diabetes duration 2.5 years). Its primary endpoint was HbA1c. With the treatment-regimen estimand, HbA1c fell 1.69, 1.86, and 1.94 percentage points on 4, 9, and 12 mg versus 0.81 on placebo (differences -0.88 to -1.12 points, all p<0.0001), and body weight fell 11.5%, 13.9%, and 15.3% versus 2.6%. GI events were mostly mild to moderate, discontinuation for adverse events was 2–5% on retatrutide, and no severe hypoglycemia was reported[15]. Like TRIUMPH-2, it had no active comparator.
Practical takeaway: what this means for T2D adults today
Retatrutide is investigational only. Practical implications:
- Retatrutide cannot be prescribed for T2D today. It is not FDA-approved for any indication. Any source claiming to dispense “retatrutide” outside an authorized clinical trial is operating outside the FDA-regulated supply chain. See retatrutide buy / regulatory sourcing evidence for the regulatory framing.
- The closest FDA-approved precedent for T2D is tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist. Mounjaro was approved May 13, 2022 (Drugs@FDA ApplNo 215866). SURPASS-1 through SURPASS-5 establish the Phase 3 evidence base.
- For T2D adults already on metformin who need intensification — the conversation today is between continuing metformin, adding an SGLT2 inhibitor, adding a selective GLP-1 receptor agonist (semaglutide or dulaglutide), adding the dual GIP/GLP-1 agonist tirzepatide, or moving to basal insulin, all based on individualized cardiorenal, weight, and tolerance considerations. See tirzepatide-metformin combination evidence for the closest approved multi-receptor precedent on a metformin background.
- If retatrutide is FDA-approved after Lilly’s planned 2027 filing — the practical management considerations (titration schedule, GI side-effect timeline, insulin/sulfonylurea dose adjustment for hypoglycemia mitigation, renal-impairment use) will mirror the existing tirzepatide and semaglutide playbooks but with retatrutide-specific dosing and labeling. Until then, those decisions remain theoretical. The kidney evidence is earlier still: retatrutide’s kidney data come from a Phase 2 post-hoc analysis, and the dedicated TRANSCEND-CKD results are not yet published.
- Defer to a licensed prescriber for any treatment decision.
Frequently Asked Questions
Further reading
- Top retatrutide studies
- GLP-1 diabetes medication interactions cheat sheet
- STEP-2 trial deep-dive (semaglutide in adults with type 2 diabetes)
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Retatrutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Semaglutide · Drugs and brands
- Dulaglutide · drug
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Titration · Dosing
Retatrutide (LY3437943) is an investigational compound. It is NOT FDA-approved for type 2 diabetes or for any other indication, anywhere worldwide as of October 2026. Treatment decisions for type 2 diabetes must be made with a licensed prescriber using FDA-approved medications. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.
References
- 1.Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. n=281 across 8 arms (placebo, dulaglutide 1.5 mg, retatrutide 0.5 mg, 4 mg esc, 4 mg no-esc, 8 mg slow esc, 8 mg fast esc, 12 mg esc). Primary endpoint HbA1c at 24 weeks. LS-mean HbA1c change: -0.43% / -1.39% / -1.30% / -1.99% / -1.88% / -2.02% (retatrutide arms ascending dose) vs -0.01% placebo and -1.41% dulaglutide. 8 mg slow esc (p=0.0019) and 12 mg (p=0.0002) significantly greater than dulaglutide. Bodyweight at 36 wk: -3.19% to -16.94% across retatrutide doses vs -3.00% placebo and -2.02% dulaglutide. NO severe hypoglycemia. No deaths. Lancet. 2023. PMID: 37385280.
- 2.Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Original pharmacology paper describing the molecular design of retatrutide and the GIP-favored receptor activity profile (more GIPR activity, balanced GCGR and GLP-1R activity) intended to balance glucagon-mediated energy expenditure against hyperglycemia risk. Cell Metab. 2022. PMID: 35985340.
- 3.Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cryo-EM structural paper describing simultaneous engagement of GLP-1R, GIPR, and GCGR by retatrutide and the structural basis for the triple-agonist pharmacology. Cell Discov. 2024. PMID: 39019866.
- 4.Urva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Mechanistic study confirming retatrutide produces measurable delayed gastric emptying — consistent with the general incretin class and relevant to the dose-dependent GI side-effect profile. Diabetes Obes Metab. 2023. PMID: 37311727.
- 5.Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. DXA substudy of Rosenstock 2023. n=189 enrolled; n=155 baseline DXA; n=103 paired baseline + 36-week DXA. Fat mass % reduction: 4.9% / 15.2% / 26.1% / 23.2% (retatrutide 0.5, 4 mg pooled, 8 mg pooled, 12 mg) vs 2.6% dulaglutide and 4.5% placebo. Proportion of lean mass loss to total weight loss similar to other obesity treatments. Lancet Diabetes Endocrinol. 2025. PMID: 40609566.
- 6.Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Appetite VAS + Eating Inventory substudy of Rosenstock 2023. n=275 T2D adults at weeks 24 and 36. Retatrutide ≥4 mg reduced overall appetite, hunger, prospective food consumption vs placebo (p<0.05). EI Perceived Hunger and Disinhibition improved at reta 8/12 mg. Reductions in Perceived Hunger and Disinhibition + increases in Dietary Restraint correlated with weight loss (r = 0.28, 0.36, 0.31). Diabetes Obes Metab. 2025. PMID: 40916752.
- 7.Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials program. Design paper for the registrational TRIUMPH Phase 3 program. TRIUMPH-2 is the dedicated T2D Phase 3 trial (ClinicalTrials.gov NCT05929079), completed June 2026 and published in The Lancet in 2026. Diabetes Obes Metab. 2026. PMID: 41090431.
- 8.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). 40-week phase 3, n=1879. Tirzepatide HbA1c reductions -2.01 / -2.24 / -2.30 percentage points (5/10/15 mg) vs -1.86 on semaglutide 1 mg. Body-weight treatment differences vs semaglutide -1.9 / -3.6 / -5.5 kg. N Engl J Med. 2021. PMID: 34170647.
- 9.Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. 40-week monotherapy trial in drug-naive T2D adults; n=478. HbA1c reductions -1.87% / -1.89% / -2.07% (tirz 5/10/15 mg) vs +0.04% placebo (all P<0.0001). Provides the monotherapy benchmark for the FDA-approved dual GIP/GLP-1 agonist. Lancet. 2021. PMID: 34186022.
- 10.Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. 40-week phase 3b, n=1201. Sema 0.5 mg -1.5% vs dula 0.75 mg -1.1% HbA1c (ETD -0.40); sema 1.0 mg -1.8% vs dula 1.5 mg -1.4% (ETD -0.41); both P<0.0001. Weight: sema 1.0 mg -6.5 kg vs dula 1.5 mg -3.0 kg (P<0.0001). Closest GLP-1-only comparator scaffold for understanding what dulaglutide 1.5 mg looks like alongside retatrutide in Rosenstock 2023. Lancet Diabetes Endocrinol. 2018. PMID: 29397376.
- 11.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
- 12.Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026). PR Newswire. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
- 13.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
- 14.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
- 15.Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. PMID: 42250575.
Related research
Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD
Retatrutide is investigational and not FDA-approved. Heerspink 2025 Kidney Int Rep post-hoc Phase 2: 12 mg cut UACR -37% at 36 wk in T2D; 8/12 mg raised eGFR +5.3/+8.5 mL/min/1.73 m2 in obesity at 48 wk. TRANSCEND-CKD Phase 2b (n=146) results not yet published.
19 min read
Retatrutide vs Ozempic: T2D Phase 2 Cross-Trial Evidence (vs SUSTAIN-7)
Indirect T2D comparison: retatrutide 12 mg -2.02% HbA1c (phase 2) and -18.8% body weight at 80 wk (TRIUMPH-2, placebo-controlled) vs Ozempic 1.0 mg -1.8% HbA1c / -6.5 kg (SUSTAIN-7). Ozempic FDA-approved 2017; retatrutide investigational.
12 min read
Retatrutide Dosage: TRIUMPH-1 Escalation Ladder + Clinical Evidence
Retatrutide (Eli Lilly LY3437943) is dosed weekly subcutaneously and escalated 2 mg to 4 mg to 6 mg to 9 mg to 12 mg in 4-week steps in TRIUMPH-1 — about 20 weeks to reach the max 12 mg dose. Pre-approval; final FDA-label dosing pending.
12 min read
Retatrutide TRIUMPH Phase 3: Latest Pipeline Update
In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.
11 min read
Ozempic Without Diabetes: Off-Label Use for Weight Loss Evidence Review
Ozempic is FDA-approved only for type 2 diabetes — off-label for weight loss is legal under 21 USC 396 but rarely insurance-covered. Wegovy is the on-label equivalent (same semaglutide, 2.4 mg vs 2.0 mg max). SELECT trial extends CV safety to non-diabetic obese adults.
12 min read
Tirzepatide vs Retatrutide: GIP/GLP-1 vs Triple Agonist Evidence
Tirzepatide hits GLP-1 + GIP. Retatrutide adds glucagon for additional energy expenditure. We walk through the mechanism math, SURMOUNT-1 vs phase 3 TRIUMPH-1 cross-trial magnitude, and the trade-offs in HR + nausea + weight loss.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $99/mo
From $139/mo
4-month plan rate
Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Read full review →From $149/mo
+ required membership